708 related articles for article (PubMed ID: 29625593)
21. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
22. Tumor regression patterns by follow-up duration in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
Kong M; Hong SE
J Radiat Res; 2017 Mar; 58(2):232-237. PubMed ID: 27738079
[TBL] [Abstract][Full Text] [Related]
23. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.
Chan AT; Teo PM; Leung TW; Leung SF; Lee WY; Yeo W; Choi PH; Johnson PJ
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):569-77. PubMed ID: 7558945
[TBL] [Abstract][Full Text] [Related]
24. Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.
Domingo-Musibay E; Murugan P; Giubellino A; Sharma S; Steinberger D; Yuan J; Hunt MA; Lou E; Miller JS
J Immunother Cancer; 2018 Jun; 6(1):58. PubMed ID: 29914578
[TBL] [Abstract][Full Text] [Related]
25. Nasopharyngeal carcinoma with mastoid recurrence after concurrent chemoradiotherapy masquerading as acute otomastoiditis.
Hu CY; Huang SF; Ho WL; Chuang WY; Chan KC
Auris Nasus Larynx; 2017 Dec; 44(6):754-757. PubMed ID: 27884592
[TBL] [Abstract][Full Text] [Related]
26. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
Sweis RF; Zha Y; Pass L; Heiss B; Chongsuwat T; Luke JJ; Gajewski TF; Szmulewitz R
J Immunother Cancer; 2018 Apr; 6(1):24. PubMed ID: 29618376
[TBL] [Abstract][Full Text] [Related]
27. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report.
Tang X; Zhou W; Huang D; Chen L; Zhang G
Front Immunol; 2021; 12():688682. PubMed ID: 34804001
[TBL] [Abstract][Full Text] [Related]
29. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
30. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
BMC Cancer; 2018 Mar; 18(1):323. PubMed ID: 29580204
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
[TBL] [Abstract][Full Text] [Related]
32. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
33. Salvage Re-irradiation with Intensity-modulated Radiotherapy, Chemotherapy Combined with Hyperthermia for Local Recurrence of Nasopharyngeal Carcinoma After Chemoradiotherapy.
Morisaki T; Ohguri T; Yahara K; Nakahara S; Kakinouchi S; Itamura H; Wakasugi T; Suzuki H; Korogi Y
J UOEH; 2021; 43(3):355-361. PubMed ID: 34483195
[TBL] [Abstract][Full Text] [Related]
34. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.
Nagasaka M; Zaki M; Kim H; Raza SN; Yoo G; Lin HS; Sukari A
J Immunother Cancer; 2016; 4():83. PubMed ID: 27895920
[TBL] [Abstract][Full Text] [Related]
35. Management of locally recurrent nasopharyngeal carcinoma.
Lee AWM; Ng WT; Chan JYW; Corry J; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Strojan P; Suárez C; Vermorken JB; Yom SS; Ferlito A
Cancer Treat Rev; 2019 Sep; 79():101890. PubMed ID: 31470314
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
Chua DT; Wei WI; Sham JS; Cheng AC; Au G
Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
[TBL] [Abstract][Full Text] [Related]
37. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study.
Ferrari D; Chiesa F; Codecà C; Calabrese L; Jereczek-Fossa BA; Alterio D; Fiore J; Luciani A; Floriani I; Orecchia R; Foa P
Oncology; 2008; 74(3-4):158-66. PubMed ID: 18714164
[TBL] [Abstract][Full Text] [Related]
38. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Choi B; McBride A; Scott AJ
Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
40. Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines.
Simo R; Robinson M; Lei M; Sibtain A; Hickey S
J Laryngol Otol; 2016 May; 130(S2):S97-S103. PubMed ID: 27841121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
